Prenetics Global Q2 Loss Widens, Lifts FY25 Revenue Guidance; Stock Up

(RTTNews) - Prenetics Global Ltd (PRE), a health science company, Friday reported a widened loss in the second quarter despite improved revenue, mainly hurt by direct costs and expenses. However, the firm lifts the revenue guidance range for the full year 2025.

Loss for the period expanded to $12.73 million from $11.15 million in the prior year.

Loss per share widened to $0.94 from $0.88 in the last year.

Loss from continuing operations widened to $10.92 million from $8.90 million a year ago.

Loss per share from continuing operations widened to $0.82 from $0.73 a year ago.

However, Revenue improved 594.9 percent to $17.68 million from $2.54 million in the prior year.

Looking forward, Prenetics increased its full-year 2025 revenue guidance range to $85-100 million from the earlier announced $80-100 million range and expects to achieve breakeven by the first quarter of 2026.

Also, Danny Yeung, Chief Executive Officer and co-founder, added, "With IM8 currently generating $5.9 million in monthly revenue in August, we aim to hit $9 million per month by the end of the year, which would solidify our path to extraordinary achievement."

In addition, the firm reported that divestment of ACT Genomics to Delta Electronics, Inc., with gross proceeds to Prenetics of $46.3 million, as settlement is progressing with closure expected in the fourth quarter of 2025.

Currently, PRE is moving up 14.11 percent, to $10.11 on the Nasdaq.